What is the most likely diagnosis in a patient with chronic kidney disease who has three days of chest pain and severe hypertension (190/100 mm Hg)?

Hypertensive Emergency with Acute Coronary Syndrome

This CKD patient presenting with 3 days of chest pain and severe hypertension (190/100 mmHg) most likely has a hypertensive emergency with acute coronary syndrome (ACS), specifically unstable angina or non-ST elevation myocardial infarction (NSTEMI).

Diagnostic Rationale

This clinical presentation meets criteria for a hypertensive emergency because:

• Blood pressure >180/120 mmHg with target organ damage (chest pain suggesting myocardial ischemia) defines a hypertensive emergency requiring immediate intervention 1
• The 3-day duration of chest pain in a CKD patient with severe hypertension strongly suggests ongoing myocardial ischemia or infarction 1
• CKD patients have 10-30 times higher cardiovascular mortality than the general population, making ACS the most likely serious diagnosis 1, 2

Key Diagnostic Considerations in CKD Patients

Cardiac biomarkers require careful interpretation:

• Troponin elevations are common in CKD even without acute MI due to chronic cardiac injury 1
• Look for absolute changes (rise and/or fall) in troponin rather than single elevated values to differentiate acute MI from chronic elevation 1
• High-sensitivity troponin maintains diagnostic accuracy in CKD; threshold <5 ng/L can rule out myocardial injury 1

ECG findings need comparison:

• Differentiate new ECG changes from pre-existing abnormalities common in CKD (left ventricular hypertrophy, electrolyte disturbances) 1
• New ST-segment changes or T-wave inversions support acute ischemia 1

Immediate Management Approach

Step 1: ICU Admission and Monitoring

• Admit to intensive care unit immediately for continuous BP and cardiac monitoring 1
• Obtain 12-lead ECG, serial troponins, renal function, and electrolytes 1

Step 2: Blood Pressure Management

For this patient WITHOUT compelling conditions (no aortic dissection, no pulmonary edema):

• Reduce mean arterial pressure by no more than 25% within the first hour 1
• Then, if stable, reduce to 160/100 mmHg within 2-6 hours 1
• Avoid excessive BP reduction that may precipitate renal, cerebral, or coronary ischemia 1

Preferred IV antihypertensive agents:

• Nitroglycerin (5-100 mcg/min IV) is first-line for coronary ischemia 1
• Labetalol (0.3-1.0 mg/kg slow IV bolus or 0.4-1.0 mg/kg/h infusion) as alternative 1
• Avoid short-acting nifedipine due to risk of precipitous BP drops causing ischemia 1

Step 3: ACS-Specific Treatment

Antiplatelet therapy:

• Aspirin and P2Y12 inhibitor (clopidogrel preferred in advanced CKD) 1
• Dose adjustment NOT required for oral antiplatelet agents in CKD 1
• Insufficient safety data for P2Y12 inhibitors in stage 5 CKD (eGFR <15 mL/min/1.73m²) 1

Anticoagulation:

• Use with caution; CKD patients have increased bleeding risk 1
• Dose adjustment required for most anticoagulants based on creatinine clearance 1

Early invasive strategy:

• Consider coronary angiography despite higher procedural risk in CKD 1
• Benefits decline with worsening renal function but still recommended when revascularization is feasible 1
• Use isosmolar contrast agents to minimize contrast-induced nephropathy risk 1

Critical Pitfalls to Avoid

Do not dismiss elevated troponin as "chronic CKD elevation" without assessing for dynamic changes 1

Do not lower BP too rapidly - excessive reduction can worsen coronary, cerebral, and renal perfusion 1

Do not withhold evidence-based ACS therapies solely based on CKD diagnosis, though dose adjustments are essential 1

Do not use nephrotoxic contrast without adequate hydration if angiography is performed 1

Prognosis

• CKD patients presenting with chest pain have 40% rate of MI, heart failure, or death at 30 days when creatinine clearance <47 mL/min 2
• Untreated hypertensive emergencies carry >79% one-year mortality with median survival of 10.4 months 1
• Heart failure development is the most common in-hospital complication, occurring in 36.5% of advanced CKD patients 2